CervoMed公司宣布了一项私募融资计划,并披露了其未来战略重心:公司将致力于寻求战略合作伙伴,以推动其核心候选药物Neflamapimod进入针对路易体痴呆症的第三阶段临床试验。这一举措旨在为关键性临床研究获取必要资源,加速该疗法的开发进程。
CervoMed公司宣布了一项私募融资计划,并披露了其未来战略重心:公司将致力于寻求战略合作伙伴,以推动其核心候选药物Neflamapimod进入针对路易体痴呆症的第三阶段临床试验。这一举措旨在为关键性临床研究获取必要资源,加速该疗法的开发进程。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.